Nevertheless, previous studies have tested AD-01 as a preclinical FKBPL-based peptide candidate therapeutic in various in vivo models of cancer [13,81,82] whereas ALM201 (a clinical FKBPL-based peptide candidate therapeutic) was also tested in Phase I clinical trials [14], showing favourable safety profile. This evidence concerns the gene FKBPL and cancer.